Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 17/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132010 | 1.00 | HDAC4 (0.39) | HDAC4HDAC8ALOX5PPARGPTPN22 | |
| SCHEMBL4122907 | 0.85 | HDAC4 (0.41) | HDAC4HDAC8ALOX5PPARGPTPN22 | |
| SCHEMBL4122909 | 0.85 | HDAC4 (0.41) | HDAC4HDAC8ALOX5PPARGPTPN22 | |
| SCHEMBL4125493 | 0.75 | ALOX5 (0.38) | ALOX5 | |
| SCHEMBL4125487 | 0.75 | ALOX5 (0.38) | ALOX5 | |
| SCHEMBL4141062 | 0.73 | PTPN1 (0.42) | ALOX5PPARG | |
| SCHEMBL4141057 | 0.73 | PTPN1 (0.42) | ALOX5PPARG | |
| SCHEMBL4128880 | 0.72 | HDAC4 (0.44) | HDAC4HDAC8ALOX5PPARGPTPN22 | |
| SCHEMBL4128877 | 0.72 | HDAC4 (0.44) | HDAC4HDAC8ALOX5PPARGPTPN22 | |
| SCHEMBL4634778 | 0.72 | PTGER3 (0.37) | HDAC4HDAC8ALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| EP-1934192-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2008-06-25 | — | — | EP | claimed |
| WO-2007032028-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-03-22 | — | — | WO | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | HDAC4 2224/4885HDAC8 2162/4885ALOX5 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.